Cardiac CT in 2023: From Anatomy to Physiology to Plaque Burden and …

Michael Gallagher

AHA 2022: Chlorthalidone Compared to Hydrochlorothiazide for the Pre…

AHA 2022 Conference Coverage

A. Ishani

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

Northwestern Medicine: The Connection Between Diabetes and Heart Dis…

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah, R. Kushner

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Anti-Obesity Medications

Michigan Medicine

D. H. Griauzde

Obesity and Heart Health: Weighing the Facts

The North American Thrombosis Forum (NATF)

K. D. Palmer Emrich

Panel Discussion: Hypertension Management and Coronary Calcium Scori…

Scripps Health

D. Cork, C. Mende, A. Robinson

Choosing the Optimal Blood Pressure Medication for My Hypertensive P…

Rivka Ayalon

Natural Options for Blood Sugar: What’s the Evidence?

Integrative Medicine - Astrid Pujari

A. Pujari

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

Is Obesity Management the Next Frontier?

Canadian Collaborative Research Network

A. Michael Lincoff

Controlling Blood Pressure in the Patient with HFpEF

MUSC Cardiology

J. Basile

Stopping GLP-1 Receptor Agonist/Dual Agonist Therapy: When and How S…

Alyssa Lampe Dominguez

SGLT2 Inhibitors and Heart Failure in Type-2 Diabetes Mellitus

Javed Butler

Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists

Ezekiel Emanuel

Treating Hypertension: Goals and New Strategies for Achieving Them

San Diego Heart Failure Symposiums

J. H. Ix

Year in Review - Obesity and Cardiovascular Kidney Syndrome: New Goa…

Samina Yunus